$6.90
1.00% yesterday
Nasdaq, Sep 10, 10:00 pm CET
ISIN
US62855J1043
Symbol
MYGN

Myriad Genetics, Inc. Stock price

$6.90
+0.71 11.47% 1M
-2.70 28.13% 6M
-6.81 49.67% YTD
-20.14 74.48% 1Y
-16.45 70.45% 3Y
-6.41 48.16% 5Y
-31.49 82.03% 10Y
-3.49 33.59% 20Y
Nasdaq, Closing price Wed, Sep 10 2025
-0.07 1.00%

Key metrics

Basic
Market capitalization
$642.0m
Enterprise Value
$627.0m
Net debt
positive
Cash
$74.0m
Shares outstanding
93.0m
Valuation (TTM | estimate)
P/E
negative | 1,100.0
P/S
0.8 | 0.8
EV/Sales
0.8 | 0.7
EV/FCF
negative
P/B
1.7
Financial Health
Equity Ratio
68.2%
Return on Equity
-18.1%
ROCE
-15.9%
ROIC
-13.1%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$832.9m | $839.0m
EBITDA
$-16.8m | $21.0m
EBIT
$-75.8m | $5.3m
Net Income
$-396.1m | $580.0k
Free Cash Flow
$-47.7m
Growth (TTM | estimate)
Revenue
3.8% | 0.2%
EBITDA
60.4% | 177.6%
EBIT
26.1% | 106.1%
Net Income
-154.7% | 100.5%
Free Cash Flow
66.8%
Margin (TTM | estimate)
Gross
70.4%
EBITDA
-2.0% | 2.5%
EBIT
-9.1%
Net
-47.6% | 0.1%
Free Cash Flow
-5.7%
More
EPS
$-4.3
FCF per Share
$-0.5
Short interest
14.2%
Employees
3k
Rev per Employee
$310.0k
Show more

Is Myriad Genetics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Myriad Genetics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Myriad Genetics, Inc. forecast:

3x Buy
15%
10x Hold
50%
7x Sell
35%

Analyst Opinions

20 Analysts have issued a Myriad Genetics, Inc. forecast:

Buy
15%
Hold
50%
Sell
35%

Financial data from Myriad Genetics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
833 833
4% 4%
100%
- Direct Costs 247 247
0% 0%
30%
587 587
6% 6%
70%
- Selling and Administrative Expenses 550 550
2% 2%
66%
- Research and Development Expense 114 114
17% 17%
14%
-17 -17
60% 60%
-2%
- Depreciation and Amortization 59 59
2% 2%
7%
EBIT (Operating Income) EBIT -76 -76
26% 26%
-9%
Net Profit -396 -396
155% 155%
-48%

In millions USD.

Don't miss a Thing! We will send you all news about Myriad Genetics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Myriad Genetics, Inc. Stock News

Neutral
Seeking Alpha
about 22 hours ago
Myriad Genetics, Inc. (NASDAQ:MYGN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 7:45 AM EDT Company Participants Samraat Raha - President, CEO & Director Ben Wheeler - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley, Research Division Presentation Yuko Oku Equity Analyst Hi, everyone. My name is Yuko Oku, and I'm on the life science...
Neutral
GlobeNewsWire
7 days ago
SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology published a study highlighting the performance of Myriad's molecular residual disease (MRD) test, Precise® MRD, in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC).
Neutral
GlobeNewsWire
8 days ago
SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies1 that included 3,532 adults with major depressive disorder (MDD).
More Myriad Genetics, Inc. News

Company Profile

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Samraat Raha
Employees 2,700
Founded 1991
Website myriad.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today